BLOPEPBOLANG BIOTECHNOLOGY

Cyclic melanocortin analogue

PT-141

PT-141 is a cyclic melanocortin analogue studied in receptor-related signaling and clinical pharmacology. The cited formulation is distinct from this research listing.

SKU: P41
BLOPEP vial — representative image
Representative image
Quantity per vial

Availability: To be confirmed

10-vial kit

10 × 10 mg = 100 mg / box

$119.00 / boxCalculated equivalent: $11.90 per vial. Sold by package.

Catalog price in USD.

Requested: 10 vials · 100 mg

Products subtotal$119.00

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Human study · Study formulation · Healthy men and participants with erectile dysfunction

Pharmacodynamic response

Placebo-controlled experiments assessed an intranasal PT-141 formulation. Reported adverse events included flushing and nausea.

Diamond et al., 2004 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

PT-141 — cyclic melanocortin analogue. The literature identity must be matched to the documented chemical form and composition of the supplied material.

The melanocortin analogue was assessed through plasma exposure and pharmacodynamic response after an intranasal formulation. Placebo comparisons and stimulation conditions differed between participant groups. Pharmacokinetics and tolerability belong to the studied route and design.

  • Melanocortin receptors

Diamond et al., 2004

Studied findings 1
Human study · Study formulation

Pharmacodynamic response

Healthy men and participants with erectile dysfunction

Placebo-controlled experiments assessed an intranasal PT-141 formulation. Reported adverse events included flushing and nausea.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Diamond et al., 2004

Sources and studies 2Peptide Monographs
  1. PT-141 — PubChem molecular identity

  2. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.

    Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB · 2004 · International journal of impotence research

    DOI: 10.1038/sj.ijir.3901139

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Peptide
Molecular formula (literature identity)
C50H68N14O10
Molecular weight (literature identity)
1025.2 g/mol
SKU
P41
Container or format
vial
Amount per unit
10 mg
Units per package
10
Nominal content per package
100 mg
Source commercial specification
10 mg

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Look up batch

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.

Other materials in this area

View category →